Resource Center

Medication Updates

Year:	Medication: Abilify (aripiprazole) Addyi Antipsychotics Aripiprazole Aristada Belsomra Brintellix Buprenorphine and naloxone Probuphine Clozapine Chantix and Zyban Cymbalta Daytrana Diazepam Effexor Farxiga Fentanyl and Opioids Geodon Hysingla ER Ingrezza Lunesta Methylphenidate Naloxone/Evzio Naltrexone Olanzapine Olanzapine/Zyprexa Opioids Opioids and Benzodiazepines Rexulti Tanzeum Targiniq ER Tramadol Treatment for Alcohol Use Disorder Vraylar Vynase Ziprasidone Zolpidem Zyprexa		General Resources: DEA Pharmacists' Manual FDA Medication Updates NIMH Mental Health Medications Guide

2017
FDA approves Ingrezza, the first drug to treat tardive dyskinesia Ingrezza (valbenazine) treats tardive dyskinesia, a neurological disorder characterized by repetitive involuntary movements.


2016
FDA revises risk of mental health side effects of Chantix and Zyban After a large clinical trial, the revised risk of mental health side effects with Chantix (varenicline) and Zyban (bupropion) was found to be lower than previously throught.	FDA issues strongest warning of risks when combining opioid pain or cough medicines with benzodiazepines The review found that combined use of these drugs results in serious side effects, including difficulty breathing and death.		Counterfeit pills fueling fentanyl and opioid crisis, DEA reports Counterfeit prescription pills containing deadly amounts of fentanyl (a synthetic opioid) have entered the US drug market.


5 new buprenorphine and naloxone medications approved Bunavail, Suboxone (tablet), Suboxone (film), Subutex, and Zubsolv have been approved.	FDA approves first buprenorphine implant Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence, has been approved as a six-month implant.		FDA adds new warning to all olanzapine-containing products The new warning describes the rare but severe condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a skin reaction.


FDA warns about impulse-control problems associated with aripiprazole (Abilify, Abilify Maintena, Aristada) FDA reports that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of aripiprazole, an antipsychotic.


2015
FDA approves Aristada (aripiprazole lauroxil) to treat schizophrenia FDA approved Aristada extended release injection to treat adults with schizophrenia.	FDA approves Vraylar (cariprazine) to treat schizophrenia and bipolar disorder Vraylar capsules approved to treat schizophrenia and bipolar disorder in adults.	FDA modifies monitoring for neutropenia in patients using clozapine; approves new REMS program The FDA is changing the requirements for clozapine to address safety concerns about neutropenia, a serious blood condition. The FDA also approves new shared REMS program to improve monitoring and treatment of patients with severe neutropenia.


FDA approves first drug treatment for sexual desire disorder The FDA has approved Addyi (flibanserin) to treat acquired, generalized hypoactive sectual desire disorder (HSDD) in premenopausal women.	FDA warns of name confusion with Brintellix (vortioxetine) and Brilinta (ticagrelor) Reports of confusion between Brintellix (an antidepressant) and Brilinta (an anti-blood clotting medication) have resulted in the wrong medication being prescribed or dispensed.	FDA approves Rexulti (brexpiprazole) to treat schizophrenia and as an add-on for major depressive disorder Rexulti approved to treat adults with schizophrenia and as an add-on with antidepressants for major depressive disorder.


FDA warns of counterfeiting issue with Diazepam purchased online Diazepam purchased on the internet runs the potential risk of being counterfeit, the FDA reports. 700 adverse reactions have been reported in patients taking mislabeled Diazepam.	FDA reports permanent skin-color changes with use of Daytrana patch (methylphenidate transdermal system) The FDA is warning that use of the Daytrana patch (methylphenidate transdermal system) for ADHD may lead to permanent loss of skin color.	First Generic Abilify (aripiprazole) approved by FDA Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.


New Guidance on Medication-Assisted Treatment for Alcohol Use Disorder SAMHSA guide for expanding use of medication in clinical practice for the treatment of alcohol use disorder.	FDA expands uses of Vyvanse to treat binge-eating disorder Vynase (lisdexamfetamine dimesylate) is now approved to treat binge-eating disorder in adults.	FDA reviews Zyprexa Relprevv The FDA study of two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv were inconclusive.


Extended-Release Injectable Naltrexone New SAMHSA guidance on the use of medication assisted treatment with extended-release injectable naltrexone for the treatment of opioid use disorder.


2014

Ziprasidone: FDA Warning FDA reporting mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reactions.	FDA approves Hysingla ER This extended-release, single-entity hydrocodone product has abuse-deterrent properties		Recall of Effexor issued by Manufacturer Sun Pharmaceutical Industries Ltd. recalled 68,000 bottles of venlafaxine (Effexor) this week, according to a report in the Wall Street Journal.


Sleep Drug Belsomra approved by FDA Approved for use as needed to treat insomnia. Belsomra is the first orexin receptor antagonist to be approved.	FDA approves Targiniq ER Targiniq ER is an extended-release pain reliever with abuse-deterrent properties - contains oxycodone and naloxone.		First-Generation vs Second-Generation Antipsychotics in Adults: Comparative Effectiveness AHRQ clinician summary of systematic review examining their comparative effectiveness, benefits, and adverse effects.


Tramadol placed in Schedule IV of Controlled Substances Act Schedule IV controlled substances regulatory requirements apply to tramadol as of 8/18/14.	FDA approves Farxiga to treat type 2 diabetes Farxiga (dapaglifozin) tablets to improve glycemic control in adults with type 2 diabetes.		FDA approves Tanzeum to treat type 2 diabetes Tanzeum is a glucagon-like peptide-1 receptor agonist that helps normalize blood sugar levels.


Lunesta/Eszopiclone Containing Sleep Aids FDA warns that Lunesta can cause next-day impairment. Recommended starting dose of1 mg at bedtime.	FDA approves hand-held auto-injector to reverse opioid overdose Evzio delivers a single dose of naloxone via hand-held auto-injector